Oncolys BioPharma Inc. (4588) Stock Price

Oncolytics Biopharma is a drug discovery biotech company developing viral therapies for cancer and treatments for severe viral infections. Its pipeline is primarily built around OBP-301 and OBP-702 in the cancer viral therapy field, and OBP-2011 in the severe viral infection field. Additionally, OBP-601, originally developed as an HIV treatment, is now being developed as a therapy for neurological disorders.

Oncolytics Biopharma operates using a hybrid business model combining licensing and pharmaceutical company models. Historically, the company has advanced pipeline development and then licensed candidates to pharmaceutical companies, generating revenue through upfront payments, milestone payments, and royalties. Going forward, the company plans to also pursue a pharmaceutical company model by obtaining its own manufacturing and marketing approvals to accelerate commercialization.

Oncolytics Biopharma's key pipeline includes cancer therapeutic OBP-301, next-generation oncolytic virus OBP-702, viral infection treatment OBP-2011, diagnostic OBP-401, and HDAC inhibitor OBP-801. Through developing these candidates, the company aims to address medical needs in cancer and severe infection treatment. OBP-301 is being developed specifically for solid tumors including esophageal cancer.

To commercialize its cancer viral therapy OBP-301, Oncolytics Biopharma has entered into a sales partnership agreement with Fujifilm Toyama Chemical for Japan. In Taiwan, the company has licensed commercialization rights to Medigen. OBP-301 is an oncolytic virus that selectively replicates in cancer cells and destroys them, with expected synergistic effects when combined with radiation therapy and immune checkpoint inhibitors.

Oncolytics Biofarma is a drug discovery biotech venture company advancing the development of cancer viral therapies and treatments for severe viral infections. The company aims to provide new treatment options for cancer, primarily centered on the oncolytic virus OBP-301 and next-generation virus OBP-702, while also developing OBP-2011 as a treatment for severe viral infections.

The company employs a hybrid business model combining licensing and pharmaceutical company operations. To date, it has licensed developed pipelines to pharmaceutical companies, generating revenue through upfront payments and royalties. Going forward, the company plans to accelerate commercialization by also pursuing its own pharmaceutical company model, obtaining manufacturing and marketing approvals independently.

Oncolytics Biofarma's key pipeline includes the cancer treatment OBP-301, next-generation oncolytic virus OBP-702, and viral infection treatment OBP-2011. Through the development of these candidates, the company aims to address medical needs in cancer and severe infection treatment areas. In particular, OBP-301 is being developed for solid tumors including esophageal cancer.

To advance OBP-301 commercialization, the company has entered into a sales partnership agreement with Fujifilm Toyama Chemical for Japan. In Taiwan, it has licensed commercialization rights to Medigen. OBP-301 is an oncolytic virus that selectively replicates in cancer cells and destroys them, with expected synergistic effects when combined with radiation therapy and immune checkpoint inhibitors.